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Objective—Studies exploring the immunologic effects of maraviroc (MVC) have produced 
mixed results; hence it remains unclear whether MVC has unique immunologic effects in 
comparison to other antiretroviral drugs. We sought to determine whether MVC has differential 
effects compared to tenofovir disoproxil fumarate (TDF) during initial antiretroviral therapy.
Design—Prospective study in AIDS Clinical Trials Group A5303, a double-blind, placebo-
controlled trial (N=262) of MVC versus TDF, each combined with boosted darunavir and 
emtricitabine
Methods—A total of 31 cellular and soluble biomarkers were assayed at weeks 0 and 48. 
Polychromatic flow cytometry was performed on cryopreserved peripheral blood mononuclear 
cells (PBMC). Soluble markers were assayed in plasma using ELISA kits. Analyses were as-
treated.
Results—Analyses included 230 participants (119 in MVC arm and 111 in TDF arm). Over 48 
weeks of treatment, no significant differences were detected in declines in markers of 
inflammation and activation with MVC versus TDF. A greater CD4+ T-cell count increase (median 
+234 cells/μl vs. +188 cells/μl, p=0.036), a smaller CD8+ T-cell count decrease (−6 cells/μl vs. 
−109 cells/μl, p=0.008) and a smaller CD4+:CD8+ ratio increase (0.26 vs. 0.39, p=0.003) occurred 
with MVC. Among participants with baseline CD4+:CD8+ ratio<1, smaller proportion of MVC 
group normalized to ratio >1 at week 48 (15% and 36%, p<0.001).
Conclusions—MVC resulted in less improvement in CD4+:CD8+ ratio driven by greater 
increase in CD4+ count but smaller decline in CD8+ count. Changes in soluble or cellular 
biomarkers of inflammation and immune activation were not different between MVC and TDF.
Keywords
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Introduction
HIV-induced immune dysfunction is not completely restored by ART [1]. Elevated soluble 
markers of inflammation and coagulation during ART predict non-AIDS events [2]. T-cell 
populations may also remain numerically abnormal and CD4+:CD8+ T-cell ratio often fails 
to normalize to >1 despite viral suppression [3]. The likelihood of attaining CD4+:CD8+ T-
cell ratio >1 may be influenced by the ART regimen [4], and a low ratio independently 
predicts non-AIDS defining events and death [3, 5]. Studies exploring the immunologic 
effects of maraviroc (MVC) have produced mixed results, hence it remains unclear whether 
MVC has unique immunologic effects in comparison to other antiretroviral drugs [6, 7, 8].
We recently reported less bone loss in 48 weeks of an initial MVC-containing regimen 
compared to a tenofovir disoproxil fumarate (TDF)-containing combination in AIDS 
Clinical Trials Group (ACTG) study A5303 [9]. Virologic efficacy was not different between 
the two arms [9]. Here, we present the immunology results. The immunology objective of 
A5303 was to determine whether the effects of MVC on inflammation, immune activation 
and T-cell reconstitution in the context of initial ART could be differentiated from the effects 
of TDF.
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ACTG A5303 was a phase II, prospective, double-blind, placebo-controlled, multicenter, 48-
week study of an experimental regimen (MVC arm: darunavir /ritonavir [DRV/r] 800/100 
mg + emtricitabine [FTC] 200mg + MVC 150mg QD) compared to a standard of care 
regimen (TDF arm: DRV/r 800/100 mg+ FTC 200mg + TDF 300mg QD) in antiretroviral 
(ARV)-naive adults infected with C-C chemokine receptor type 5 (CCR5)-tropic HIV-1. 
HIV-1 tropism was determined using Trofile (Monogram Biosciences, San Francisco, 
California, USA). Eligibility required HIV-1 RNA > 1,000 copies/mL and no evidence of 
active hepatitis B. Randomization was stratified by plasma HIV-1 RNA < or ≥ 100,000 
copies/mL and age < or ≥ 30 years. Details for the study designs were described in the 
primary manuscript [9]. The Institutional Review Board of each study site approved the 
protocol. Each participant provided a written informed consent (Clinicaltrials.gov identifier 
NCT01400412). The study enrolled 262 participants in the United States.
Polychromatic flow cytometry was performed in batch on week 0 and 48 cryopreserved 
peripheral blood mononuclear cells (PBMCs) from each participant. In brief, cellswere 
stained for viability with Aqua Live/Dead (Life Technologies, Eugene, Oregon, USA) 
followed by cell staining using fluorochrome-conjugated monoclonal antibodies (BD 
Biosciences, San Jose, California, USA; BioLegend, San Diego, California, USA; 
eBiosciences, Inc., San Diego, California, USA). PBMC were stained for T-cell subsets 
(CD3/CD4, CD3/CD8) and associated markers of immune activation (CD38/HLA-DR), 
senescence (CD57/CD28), and T-regulatory (CD25/FOXP3) cells. In a separate tube, PBMC 
were stained for markers of monocyte subsets (CD14/CD16/CCR2/CX3CR1), B cells 
(CD19/FcRL4), and natural killer (NK) cell subsets (CD56/CD16). All tubes were fixed in 
1% formaldehyde and analyzed within 24 h on an LSRFortessa flow cytometer (BD 
Biosciences) using BD FACSDiva software v7.0. Analysis of flow cytometry data was 
performed using FlowJo software (FlowJo, LLC, Ashland, Oregon, USA).
Frozen\thawed week 0 and 48 EDTA plasma samples were analyzed using ELISA kits for 
quantification of soluble (s) CD14, sCD163, interferon gamma induced protein (IP)-10, 
soluble tumor necrosis factor receptor (sTNFR) II, and high-sensitivity interleukin (IL)-6 (all 
Quantikine; R & D Systems, Inc., Minneapolis, Minnesota, USA). D-dimer was measured in 
citrate plasma using an ELISA kit from Diagnostica Stago, Inc. (Parsippany, New Jersey, 
USA). All ELISAs were run according to the manufacturers’ protocols.
Statistical analyses
All analyses were as-treated and included only participants who remained on their 
randomized MVC or TDF component by week 48 without an interruption in treatment of 
more than 10 weeks with available data for both baseline and week 48. Participants with 
missing data due to insufficient blood samples, data errors, or lab errors were further 
excluded from the analyses.
Wilcoxon signed rank tests were used to test for within treatment arm changes greater than 
zero; 95% confidence intervals (CI) for median changes within treatment arm were 
estimated using distribution-free method via percentiles. Stratified Wilcoxon rank sum tests 
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were used to test for treatment arm differences, stratified by the age stratum (<30 vs. ≥ 30 
years). Among participants with inverted CD4+:CD8+ ratio (ratio < 1) at baseline, treatment 
arm differences in CD4+:CD8+ ratio normalization (ratio >1) [4] over 48 weeks were 
assessed with Fisher’s tests. In addition, proportions of participants with CD4+:CD8+ ratio 
>0.4 [5] were also evaluated with Fisher’s test. Changes in soluble biomarkers and CD4+ / 
CD8+ counts were assessed on the absolute changes from baseline to week 48, whereas 
changes in percentage expression for cellular biomarkers were assessed as percentage 
change (i.e. 100% x (week 48 – week 0) / week 0).
All statistical tests were two-sided and presented with nominal p-values. To account for the 
large number of soluble and cellular markers tested, p-values for treatment arm comparisons 
for these markers were conservatively interpreted at the 0.5% nominal level of significance; 
conclusions regarding p-values between 0.05 and 0.005 were tempered. Given the prior data 
with MVC with respect to changes in CD4+ T-cell count changes, inferences regarding 
CD4+, CD8+, and their ratio were interpreted at a conventional 5% level. Analyses were 
conducted using SAS statistical software 9.4 (SAS Institute Inc., Cary, North Carolina, 
USA).
Results
A total of 230 participants were in the as-treated population (119 in the MVC arm and 111 
in the TDF arm). There were 9% female; 44% White, 31% Black, 22% Hispanic. The 
median age at baseline was 33 years, median VL was 4.5 log10 copies/mL and median CD4+ 
count was 390 cells/μl.
CD4+ and CD8+ T-cell Counts
A greater CD4+ T-cell count increase from baseline to week 48 was observed in the MVC 
arm (median change 234 cells/μl [Q1, Q3: 131, 327]) than in the TDF group (188 cells/μl 
[94, 304]; p=0.036). While significant within arm decreases in CD8 T-cell count were 
observed over 48 weeks in TDF arm (median change −109 cells/μl [−340, 59]; p<0.001), 
these were not apparent with MVC (−6 cells/μl [−252, 175]; p=0.51); between arm 
comparison (p=0.008). In turn, a smaller increase in CD4+:CD8+ ratio from baseline to week 
48 was observed in the MVC arm than in the TDF arm (p=0.003); median (Q1, Q3) change 
0.26 (0.13, 0.43) in the MVC arm compared with 0.39 (0.21, 0.54) in the TDF arm (Table 1).
Among 215 participants with CD4+:CD8+ ratio<1 at baseline (n=110 in MVC, n=105 in 
TDF), 15% and 36% of the participants in the MVC arm and TDF arm respectively had 
normalized CD4+:CD8+ ratio (ratio >1) at week 48 (p<0.001). Using a CD4+:CD8 ratio cut-
off of 0.4, there was no significant difference between the two arms (p=0.93): 90% and 88% 
on MVC versus TDF arm with ratio >0.4 at week 48.
Soluble biomarkers
With the exception of IL-6 and sCD14, significant declines in all soluble biomarkers from 
baseline to week 48 in both treatment arms were apparent (p<0.001). For IL-6 and sCD14, 
declines were apparent in the MVC arm (p=0.007 and 0.001, respectively) but not the TDF 
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arm (p=0.12 and 0.41, respectively). Differences between the two treatment arms were not 
apparent in any of these soluble biomarkers (p>0.10) (Table 1).
Cellular biomarkers (CD4 and CD8 subsets, monocytes, B cells and NK cells)
Although significant within-group changes in a range of the CD4, CD8, or monocyte subsets 
examined were apparent, there was no evidence of differences between MVC and TDF arms 
(p>0.05) (Table 2). Of note, while the treatment arm difference in %increase in %CD56HI/
CD16-(NK cells) approached our conservative threshold for statistical significance 
(p=0.007; median %change 4% [−23%, 64%] in the MVC arm compared to 30% [−2%, 
89%] in the TDF arm the magnitude of these increases on an absolute scale were small 
(median absolute change 0.2% vs. 1.0%).
Discussion
In this randomized trial, initiating ART with a MVC-containing regimen resulted in 
significant declines in all soluble markers (IL-6, IP-10, sTNF-rII, sCD14, d-dimer, and 
sCD163) from weeks 0 to 48. Significant declines in the soluble biomarkers occurred in the 
TDF arm with the exception of IL-6 and sCD14. Overall, no significant differences were 
detected between MVC and TDF in the decline in any soluble marker in our study. Changes 
from baseline to week 48 in cellular markers of T-cell activation and senescence, and in 
monocyte, B cell and NK cell populations were also not different between MVC and TDF. 
We saw a treatment arm difference in %CD56HI/CD16-(natural killer cells) that was 
marginally significant, but the magnitudes of the increases were too small to be considered 
clinically meaningful. Given the comparable virologic efficacy of the MVC and TDF 
regimens in our study [9], the immunologic changes in both arms were likely driven mainly 
by suppression of viral replication. Of note, ACTG A5260s also found no significant decline 
in IL-6 and sCD14 levels among participants who received TDF/FTC plus DRV/r, although 
both markers declined significantly in the TDF/FTC plus raltegravir arm of the study [10].
Our results demonstrate that MVC produces a greater numerical increase in CD4+ T-cells 
than TDF in initial ART (difference in median increase of 46 cells/μl), consistent with the 
greater improvement reported with MVC relative to efavirenz [11]. Meta regression of data 
from 17 clinical trials involving treatment-experienced participants also demonstrated that 
MVC use was associated with an additional gain of 30 CD4+ T-cells/μl at 24 weeks [12]. An 
effect of MVC on CD4+T-cell counts was previously demonstrated even when virologic 
suppression was not achieved [13].
CD8+ T-cell count decreased significantly in the TDF arm but not the MVC arm. A potential 
explanation for this is that CD8+ T cells are more likely to express CCR5 than CD4+ T cells 
in circulation [6]; hence, CCR5 blockage may preferentially prevent trafficking of CD8+ 
cells out of circulation, and result in a differential expansion of CD8+ T cells. Consistent 
with this, although the CD4+: CD8+ T-cell ratio increased in both arms, the improvement 
was significantly smaller in the MVC arm. Further, among study participants with an 
inverted CD4+: CD8+ ratio (ratio <1) at baseline, normalization to a ratio greater than 1 
occurred less frequently in the MVC arm. Although the clinical implications of these 
findings are uncertain, inversion of the CD4+: CD8+ ratio is a hallmark of 
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immunosenescence and an independent predictor of mortality [14]. Nevertheless, our 
findings on CD4+:CD8+ T-cell repopulation should be interpreted with caution since 
participants were followed for 48 weeks only and there is no evidence that MVC increases 
long-term morbidity or mortality. Using a CD4+:CD8+ ratio cut-off of 0.4 at week 48, which 
has been linked with risk of non-AIDS events during ART [3,5], we found no significant 
difference between MVC and TDF. Some investigators recently reported a strong association 
between use of an integrase strand transfer inhibitor in initial ART and normalization of 
CD4+:CD8+ T-cell ratio [4]. Future studies should delineate further how contemporary ART 
regimens differ in their effects on the CD4+:CD8+ T-cell ratio and also define the clinical 
consequences.
In summary, the randomized, placebo controlled A5303 clinical trial showed similar changes 
in markers of inflammation and activation in the first 48 weeks of MVC- or TDF-containing 
ART. The regimens differentiated with respect to CD4 and CD8 numerical reconstitution 
with higher CD4+T-cell gain recorded in with MVC while normalization of CD4+:CD8+ 
ratio to >1 occurred more frequently with TDF.
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Appendix: Study Sites participated in ACTG A5303
• Massachusetts General Hospital
• Brigham and Women’s Hospital
• Johns Hopkins University
• University of California, Los Aangeles CARE Center
• University of California, San Diego Antiviral Research Center
• University of California, San Francisco HIV/AIDS
• University of Miami, AIDS Clinical Research Unit
• Georgetown University
• University of Southern California
• University of Washington AIDS
• Washington University in St Louis
• Ohio State University
• University of Cincinnati




• The Miriam Hospital
• University of North Carolina, Chapel Hill
• University of North Carolina, Greensboro
• Vanderbilt University
• IHV Baltimore Treatment
• Puerto Rico AIDS Clinical Trials Unit
• The Ponce de Leon Center, Emory University
• University of Colorado Hospital
• University of Pennsylvania
• Columbia Physicians and Surgeons
• Trinity Health and Wellness Center
• Houston AIDS Research Team
• Cooper University Hospital
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• University of Rochester, Adult HIV Therapeutics
• University of Alabama
• University of South Florida
• Children’s National Medical Center
• St. Jude Children’s Research Hospital
• Texas Children’s Hospital
• University of Colorado, Denver
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